A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment.

Trial Profile

A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2013

At a glance

  • Drugs Pomaglumetad methionil (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Oct 2012 Planned End Date changed from 1 Aug 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
    • 04 Apr 2012 Planned end date changed from 1 May 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top